| Literature DB >> 26844224 |
David Noriega1, Gianluca Maestretti2, Christian Renaud3, Natale Francaviglia4, Mourad Ould-Slimane5, Steffen Queinnec6, Helmut Ekkerlein7, Frank Hassel8, Rainer Gumpert9, Pascal Sabatier10, Hervé Huet11, Miguel Plasencia12, Nicolas Theumann13, Alexander Kunsky14, Antonio Krüger15.
Abstract
This prospective, consecutive, multicentre observational registry aimed to confirm the safety and clinical performance of the SpineJack system for the treatment of vertebral compression fractures (VCF) of traumatic origin. We enrolled 103 patients (median age: 61.6 years) with 108 VCF due to trauma, or traumatic VCF with associated osteoporosis. Primary outcome was back pain intensity (VAS). Secondary outcomes were Oswestry Disability Index (ODI), EuroQol-VAS, and analgesic consumption. 48 hours after surgery, a median relative decrease in pain intensity of 81.5% was observed associated with a significant reduction in analgesic intake. Improvements in disability (91.3% decrease in ODI score) and in quality of life (increase 21.1% of EQ-VAS score) were obtained 3 months after surgery. All results were maintained at 12 months. A reduction in the kyphotic angulation was observed postoperatively (-5.4 ± 6.3°; p < 0.001), remained at 12 months (-4.4 ± 6.0°, p = 0.002). No adverse events were implant-related and none required device removal. Three patients (2.9%) experienced procedure-related complications. The overall adjacent fracture rate up to 1 year after surgery was 2.9%. The SpineJack procedure is an effective, low-risk procedure for patients with traumatic VCF allowing a fast and sustained improvement in quality of life over 1 year after surgery.Entities:
Mesh:
Year: 2015 PMID: 26844224 PMCID: PMC4710926 DOI: 10.1155/2015/173872
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1SpineJack expandable intravertebral body implant, closed and fully expanded.
Figure 2Functional principle of the SpineJack procedure.
Figure 3Operated vertebral levels.
Baseline patient characteristics.
| Traumatic VCF with osteoporosis | Traumatic VCF | Total | |
|---|---|---|---|
|
|
|
| |
| Age, mean (SD) (years) | 69.2 (12.1) | 59.5 (15.5) | 61.6 (15.3) |
| Female, | 20 (90.9%) | 31 (38.3%) | 51 (49.5%) |
| BMI, mean (SD) (kg/m2) | 25.9 (4.6) | 25.8 (3.8) | 25.8 (3.9) |
| Number of augmented vertebrae | 22 | 86 | 108 |
| Time from fracture to procedure, mean (SD) (days) | 13.9 (8.9) | 8.1 (7.1) | 9.2 (7.8) |
| Pain, VAS score, mean (SD) (cm) | 6.8 (1.9) | 6.6 (2.8) | 6.6 (2.6) |
| ODI score, mean (SD) | 70.5 (16.0) | 78.3 (19.9) | 76.6 (19.4) |
| EQ-VAS | 47.7 (21.4) | 51.1 (26.6) | 50.4 (25.5) |
Flowchart of visits according to type and age of fracture.
| Inclusion | |||||
|---|---|---|---|---|---|
|
| |||||
| Traumatic and osteoporosis associated | Traumatic only | ||||
|
|
| ||||
| <15 days | [15; 30] days | [30; 45] days | <15 days | [15; 30] days | [30; 45] days |
|
|
|
|
|
|
|
|
| |||||
| Procedure | |||||
|
| |||||
| Traumatic and osteoporosis associated | Traumatic only | ||||
|
|
| ||||
|
| |||||
| <15 days | [15; 30] days | [30; 45] days | <15 days | [15; 30] days | [30; 45] days |
|
|
|
|
|
|
|
|
| |||||
| 48 hours after surgery | |||||
|
| |||||
| Traumatic and osteoporosis associated | Traumatic only | ||||
|
|
| ||||
|
| |||||
| <15 days | [15; 30] days | [30; 45] days | <15 days | [15; 30] days | [30; 45] days |
|
|
|
|
|
|
|
|
| |||||
| 3 months after surgery | |||||
|
| |||||
| Traumatic and Osteoporosis associated | Traumatic Only | ||||
|
|
| ||||
|
| |||||
| <15 days | [15; 30] days | [30; 45] days | <15 days | [15; 30] days | [30; 45] days |
|
|
|
|
|
|
|
|
| |||||
| 12 months after surgery | |||||
|
| |||||
| Traumatic and Osteoporosis associated | Traumatic Only | ||||
|
|
| ||||
|
| |||||
| <15 days | [15; 30] days | [30; 45] days | <15 days | [15; 30] days | [30; 45] days |
|
|
|
|
|
|
|
Absolute changes (cm) and relative (%) changes in VAS score.
| Traumatic VCF with osteoporosis | Traumatic VCF | Total | |
|---|---|---|---|
| 48 h versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | −5.5 (1.9) | −5.1 (2.9) | −5.2 (2.7) |
| Median absolute changes | −5.7 | −6.1 | −6.0 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | −81.0 | −81.8 | −81.5 |
|
| |||
| 3 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | −5.5 (2.7) | −5.3 (3.0) | −5.3 (2.9) |
| Median absolute changes | −6.2 | −6.0 | −6.0 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | −90.0 | −88.0 | −88.0 |
|
| |||
| 12 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | −5.7 (2.3) | −5.5 (3.0) | −5.5 (2.9) |
| Median absolute changes | −5.2 | −6.3 | −5.8 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | −90.3 | −92.2 | −91.5 |
Figure 4Evolution of pain: median VAS score over time.
Figure 5Evolution in analgesic requirements.
Absolute and relative (%) changes in ODI score.
| Traumatic VCF with osteoporosis | Traumatic VCF | Total | |
|---|---|---|---|
| 3 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | −54.3 (26.6) | −64.3 (24.1) | −62.0 (24.9) |
| Median absolute changes | −62.0 | −73.3 | −71.3 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | −91.0 | −92.7 | −91.3 |
|
| |||
| 12 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | −60.7 (18.8) | −67.1 (24.9) | −65.7 (23.8) |
| Median absolute changes | −64.1 | −74.0 | −73.3 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | −92.9 | −95.0 | −94.9 |
Figure 6Evolution of functional disability: median ODI score over time.
Absolute and relative (%) changes in EQ-VAS score.
| Traumatic VCF with osteoporosis | Traumatic VCF | Total | |
|---|---|---|---|
| 3 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | 23.1 (25.3) | 16.6 (31.6) | 18.1 (30.2) |
| Median absolute changes | 16.5 | 12.5 | 13.0 |
| Within-group test | <.001 (Student) | <.001 (Student) | <.001 (Wilcoxon) |
| Median relative changes | 27.0 | 17.4 | 21.1 |
|
| |||
| 12 months versus baseline |
|
|
|
|
| |||
| Mean (SD) absolute changes | 29.3 (22.3) | 23.4 (28.4) | 24.6 (27.2) |
| Median absolute changes | 26.5 | 16.0 | 19.0 |
| Within-group test | <.001 (Student) | <.001 (Wilcoxon) | <.001 (Wilcoxon) |
| Median relative changes | 44.2 | 33.3 | 38.3 |
Adverse events.
| Patient number | Type of event | Time after surgery (days) | Relationship to device | Relationship to procedure | Outcome at 12 M |
|---|---|---|---|---|---|
| 11R01 | Death due to acute kidney failure aggravation with vascular obliteration of leg | 52 | No | No | Death |
|
| |||||
| 11R04 | Sigma diverticulitis (preexisting condition at inclusion) aggravation: hospitalization for diverticulitis resection | 8 | No | No | Resolved |
|
| |||||
| 11R07 | Asymptomatic adjacent vertebral fracture T11: No treatment needed (treated vertebra T12) | 99 | No | Yes | Ongoing (fracture remains stable) |
|
| |||||
| 13R06 | Prolongation of hospitalization for dislocation of posterior wall secondary to surgery which leads to sensorial deficit → surgery with wrong indication | 4 | No | Yes | Resolved |
| Breakage of screws in L3: recommendation of revision surgery but patient declined surgery | 82 | No | No | Ongoing | |
|
| |||||
| 31R04 | Posterior articular conflict due to a discopathy L4/L5 grade IV associated to a degenerative spondylolisthesis grade II Meyerding | 147 | No | No | Resolved at Day 455 |
|
| |||||
| 31R05 | Algoneurodystrophic syndrome due to calcaneum fracture resolved by decompressive surgery | 100 | No | No | Resolved |
|
| |||||
| 31R06 | Prostatic cancer | 257 | No | No | Ongoing |
|
| |||||
| 31R15 | Bleeding at the point of the skin incision just after the surgery | 2 | No | No | Resolved |
|
| |||||
| 31R16 | Spontaneous adjacent fracture T12 (treated vertebra L1) in a context of major osteoporosis aggravation: hospitalization for vertebroplasty | 19 | No | No | Resolved |
| Spontaneous adjacent fracture L2 (treated vertebra L1) in a context of major osteoporosis aggravation treatment: analgesics and Zoledronic acid monohydrate | 49 | No | No | Patient discontinued | |
| Spontaneous new fracture L4 (treated vertebra L1) in a context of major osteoporosis aggravation treatment: analgesics and Zoledronic acid monohydrate | 86 | No | No | Patient discontinued | |
| Spontaneous new fracture L5 (treated vertebra L1) in a context of major osteoporosis aggravation treatment: analgesics and Zoledronic acid monohydrate | 86 | No | No | Patient discontinued | |
|
| |||||
| 35R08 | Death due to acute respiratory syndrome | 204 | No | No | Death |
|
| |||||
| 35R11 | Hospitalization in psychiatric department | Not available | No | No | Resolved |
|
| |||||
| 36R01 | Subsequent fracture at T12 level (previous treated level L2): hospitalization for vertebroplasty | 18 | No | No | Resolved |
| Subsequent fracture at T11 level (previous treated level L2): hospitalization for vertebroplasty | 126 | No | No | Resolved | |
| Adjacent fracture at L3 level (previous treated level L2): hospitalization for vertebroplasty | 126 | No | No | Resolved | |
|
| |||||
| 36R02 | Lumbar pain | 418 | No | No | Resolved |
|
| |||||
| 38R07 | Shoulder fracture due to a fall discovered lately and treated by physiotherapy | 276 | No | No | Ongoing |
|
| |||||
| 41R02 | Collapse of treated vertebral body associated with canal compromise and hematoma leading to neurological symptoms | 16 | No | Yes | Improved |